Intel is scheduled to report second-quarter results after the closing bell Thursday, with analysts tracked by Visible Alpha unanimously neutral amid questions surrounding the company's foundry ...

Wall Street's biggest bull sees tech and AI driving an 11% stock gain, fueled by strong fundamentals, M&A activity, and ...

In the recent 13F filings, Pfizer has seen a mix of investment adjustments from 11 institutions, reflecting a divided market ...

Oppenheimer initiated coverage of the buy now, pay later firm Monday, issuing an "outperform" rating for Affirm stock.

While its shares have been lagging the market significantly, that could change in the next decade as financial results ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over ...

The pharmaceutical sector continues to stand out as a resilient and highly profitable corner of the market, even amid global ...

Shares of Johnson & Johnson climbed 6.8% in morning trading, enough to pace the S&P 500 index's SPX gainers. They were also headed for their biggest one-day gain and best postearnings reaction since ...

Pfizer (PFE), a global pharmaceutical giant that was once a pandemic darling, is now facing turbulence. Following a period of extraordinary vaccine-driven revenue, the company now faces a more ...

A retirement-ready portfolio consists of reliable, income-generating stocks that quietly compound over time. Realty Income (O ...

Accenture downgraded to neutral amid soft bookings, weak guidance, and demand uncertainty. See here to know more on ACN stock ...

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.